KPF
BBOT

K2 Principal Fund’s BridgeBio Oncology BBOT Stock Holding History

K2 Principal Fund’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,000
Closed -$1.06M – 392
2025
Q2 		$1.06M Hold
100,000
– – 0.15% 149
2025
Q1 		$1.13M Buy
+100,000
New +$1.07M 0.14% 140

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

K2 Principal Fund's BBOT Position: Q3 2025 in Review

K2 Principal Fund sold out of BridgeBio Oncology (BBOT) in Q3 2025, closing a stake of 100,000 shares — an estimated $1.06M sold.

K2 Principal Fund first reported a position in BBOT in Q1 2025 and held it in 2 quarters. The position peaked at $1.13M in Q1 2025. 42 funds tracked by Wall St. Rank hold BBOT as of Q3 2025.

  • K2 Principal Fund reported no remaining BridgeBio Oncology position as of Q3 2025 after selling out during the quarter.
  • K2 Principal Fund sold 100,000 BridgeBio Oncology shares in Q3 2025, an estimated $1.06M.
  • K2 Principal Fund first reported a position in BridgeBio Oncology in Q1 2025 and held it in 2 quarters.
  • K2 Principal Fund's BridgeBio Oncology position peaked at $1.13M in Q1 2025.
  • 42 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2025.

Based on K2 Principal Fund's 13F filing for Q3 2025, filed 13 Nov 2025.